1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Janssen persuades Scotland to reimburse Zytiga

 
• By Francesca Bruce

Janssen has managed to convince the Scottish Medicines Consortium, Scotland's health technology appraisal body, that the benefits of its anticancer Zytiga (abiraterone) do in fact justify the cost. The consortium has this week accepted the drug for use on the Scottish NHS for patients with metastatic castration resistant prostate cancer.

Janssen has managed to convince the Scottish Medicines Consortium, Scotland's health technology appraisal body, that the benefits of its anticancer Zytiga (abiraterone) do in fact justify the cost. The consortium has this week accepted the drug for use on the Scottish NHS for patients with metastatic castration resistant prostate cancer.

Janssen has succeeded where Sanofi-Aventis failed with its Taxotere (docetaxel) follow-on, Jevtana (cabazitaxel), the only other drug to demonstrate survival...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

More from Therapeutic Category

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.